Work

Characterization of vaniprevir, a hepatitis C virus NS3/4A protease inhibitor, in patients with HCV genotype 1 infection: Safety, antiviral activity, resistance, and pharmacokinetics

Year: 2013

Type: article

Study designs: Randomized Controlled Trial, Clinical Trial

Source: Antiviral Research

DOI: 10.1016/j.antiviral.2013.05.015

Authors: Eric Lawitz, Mark Sulkowski, Ira Jacobson, Walter K. Kraft, Benedict Maliakkal, Mohamed Al-Ibrahim, Stuart C. Gordon, Paul Kwo, Juergen Kurt Rockstroh, Paul Panorchan, Michelle Miller, Luzelena Caro, Richard Barnard, Peggy May Hwang, Jacqueline Gress, Erin Quirk, Niloufar Mobashery

Institutions: Johns Hopkins University, Johns Hopkins Medicine, Cornell University, Weill Cornell Medicine, Thomas Jefferson University, University of Rochester Medicine, University of Rochester, Shin Nippon Biomedical Laboratories (United States), Henry Ford Health, Henry Ford Hospital, Indiana University, University of Bonn, Merck & Co., Inc., Rahway, NJ, USA (United States)

Language: English

Topic: Hepatitis C virus research

Subfield: Hepatology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

Funder: Merck Sharp and Dohme

OpenAlex ID: W2003315968

FWCI: 2.761

Cites: 15

Cited by: 33

Related to: 10